PMID- 25903527
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20150423
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 135 Suppl 1
DP  - 2015 Feb
TI  - Guidelines for the management of cancer and thrombosis - Special aspects in 
      women.
PG  - S16-22
LID - S0049-3848(15)50434-9 [pii]
LID - 10.1016/S0049-3848(15)50434-9 [doi]
AB  - BACKGROUND: Occurrence of venous thromboembolism (VTE) in patients with cancer is 
      associated with unfavorable prognosis, and VTE treatment is less effective and 
      more complicated in cancer patients. Several women specific aspects related to 
      the underlying cancer type and VTE management need to be considered. METHODS: 
      Guidelines on VTE prevention and treatment in cancer patients issued from several 
      international bodies are reviewed with respect to women specific recommendations, 
      and general guideline recommendations are summarized. RESULTS: All guidelines 
      recommend an initial parenteral treatment, preferably with low-molecular-weight 
      heparin (LMWH), while fondaparinux or unfractionated heparin (UFH) can also be 
      used. Long-term treatment, comprising 3 to 6 months after initial anticoagulation 
      should preferably be performed with LMWH, or vitamin K antagonists (VKA), if LMWH 
      is not available. For extended treatment beyond six months, there are no specific 
      recommendations due to lack of evidence, and anticoagulation can be performed 
      with LMWH or VKA. Novel or non-VKA oral anticoagulants (NOACs) have been studied 
      in several trials in comparison to VKA in VTE patients, including 3-9% cancer 
      patients. While NOACs showed comparable efficacy and safety to VKA in those 
      cancer patients, results from trials comparing NOACs with LMWH are not available. 
      Because of the paucity of data, there are no guideline recommendations for women 
      specific cancer types or women specific issues in the prevention and treatment of 
      VTE. CONCLUSIONS: While there is agreement on general VTE management in cancer 
      patients across different international guidelines, there is insufficient 
      guidance on many women specific aspects commonly encountered during clinical 
      practice. Future trials are required that specifically and prospectively address 
      women specific issues in the management of VTE in cancer.
CI  - (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Bauersachs, Rupert M
AU  - Bauersachs RM
AD  - Vascular Medicine, Medical Department IV, Klinikum Darmstadt GmbH, D-64283 
      Darmstadt, Germany. Electronic address: bauersachs@em.uni-frankfurt.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150209
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants/standards/therapeutic use
MH  - Cardiology/*standards
MH  - Female
MH  - Humans
MH  - Internationality
MH  - Medical Oncology/*standards
MH  - Neoplasms/complications/*therapy
MH  - *Practice Guidelines as Topic
MH  - Venous Thromboembolism/complications/*therapy
MH  - Women's Health/*standards
OTO - NOTNLM
OT  - Anticoagulation
OT  - Cancer
OT  - Female gender
OT  - NOACs
OT  - Venous thromboembolism
OT  - Women
EDAT- 2015/04/24 06:00
MHDA- 2016/01/15 06:00
CRDT- 2015/04/24 06:00
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
AID - S0049-3848(15)50434-9 [pii]
AID - 10.1016/S0049-3848(15)50434-9 [doi]
PST - ppublish
SO  - Thromb Res. 2015 Feb;135 Suppl 1:S16-22. doi: 10.1016/S0049-3848(15)50434-9. Epub 
      2015 Feb 9.